20 Sep

Administering second-line antituberculous medications to children with multidrug-resistant tuberculosis: A qualitative study

“I had one father tell me his boy eats more pills than food for breakfast.” TB physician, 32 years old, South Africa

There are more than 65,000 children living with multidrugresistant tuberculosis (MDR-TB) in the world today, and, while children have excellent outcomes from MDR-TB therapy, fewer than 1%
are diagnosed and treated for their disease. Even when a child is started on a regimen containing second-line drugs to treat MDR-TB, there are significant barriers to completing successful therapy and achieving cure. Almost none of these drugs is available in a child-friendly formulation.

We completed interviews with five nurses and four physicians from Peru, South Africa, Georgia, Romania and Bangladesh about the challenges of administering second-line drugs to
children. This poster presents data and quotes from those interviews.

“Administering Second-Line Antituberculous Medications to Children with Multidrug-Resistant Tuberculosis: A Qualitative Study” (September, 2013)

15 Sep

Pediatric TB course in Dhaka, Bangladesh

On July 15 2013, the Sentinel Project, sponsored by the United States Agency for International Development’s TB CARE II project, organized “Improving the Quality of Care for Children with Drug-Resistant TB” in Dhaka, Bangladesh. The workshop was attended by a total of 35 participants, primarily pediatricians from public and private hospitals and medical colleges. Local and international experts presented on pediatric MDR TB, diagnostic and treatment challenges, strategies for ensuring treatment adherence, monitoring and infection control. A special session demonstrated the gastric aspirate, a technique used for obtaining sputum samples from very young patients.  Participants discussed and recommended priority actions for scaling up the availability of services for pediatric MDR TB patients in Bangladesh. The recommendations include establishing a working group to oversee the planning and implementation of pediatric MDR-TB activities and provide clinical guidance; the design and implementation of a pilot project on contact tracing including specimen collection and referral; conducting operational research to support policy and strategy formulations; and updating medical curricula to improve education on the management of childhood TB.

15 Sep

Poster on second-line MDR-TB medications

We are pleased to share a recent poster presentation: “Administering Second-Line Antituberculous Medications to Children with Multidrug-Resistant Tuberculosis: A Qualitative Study.” The poster was presented by Erica Lessem at the Clinical Pharmacology Workshop on New TB Drugs on September 9, 2013 in Denver Colorado. This poster presents results from a very small qualitative study of clinicians providing care to children with MDR-TB, and points to the need to improved pediatric formulations for second-line drugs.